Core Insights - The article compares Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC) to determine which stock is more attractive to value investors [1] Group 1: Zacks Rank and Earnings Outlook - HRMY has a Zacks Rank of 1 (Strong Buy), indicating a stronger improvement in its earnings outlook compared to ONC, which has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank strategy targets companies with positive earnings estimate revision trends, which is a key factor for value investors [2] Group 2: Valuation Metrics - HRMY has a forward P/E ratio of 12.33, significantly lower than ONC's forward P/E of 410.78, suggesting HRMY is more undervalued [5] - The PEG ratio for HRMY is 0.52, while ONC's PEG ratio is 9.21, indicating HRMY's expected EPS growth rate is more favorable [5] - HRMY's P/B ratio is 3.72, compared to ONC's P/B of 6.54, further supporting HRMY's valuation attractiveness [6] Group 3: Value Grades - HRMY has a Value grade of A, while ONC has a Value grade of D, highlighting HRMY's superior valuation metrics [6] - The combination of Zacks Rank and Style Scores indicates that HRMY is the better option for value investors at this time [6]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Harmony Biosciences Holdings, Inc. (HRMY) being highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Historical EPS growth rate for Harmony Biosciences is 13.5%, but projected EPS growth for this year is expected to be 30.1%, significantly higher than the industry average of 12.3% [4]. - Earnings growth is a critical factor for growth investors, with double-digit growth being a strong indicator of future stock price gains [3]. Group 2: Asset Utilization Ratio - Harmony Biosciences has an asset utilization ratio (sales-to-total-assets ratio) of 0.79, indicating that the company generates $0.79 in sales for every dollar in assets, which is significantly higher than the industry average of 0.24 [6]. - The company is also expected to achieve a sales growth of 17.7% this year, compared to the industry average of 17.2% [6]. Group 3: Earnings Estimate Revisions - The current-year earnings estimates for Harmony Biosciences have been revised upward, with the Zacks Consensus Estimate increasing by 3.6% over the past month [8]. - Positive trends in earnings estimate revisions are correlated with near-term stock price movements, further validating the company's growth potential [7]. Group 4: Overall Positioning - Harmony Biosciences has earned a Growth Score of A and holds a Zacks Rank 1 (Strong Buy), positioning it well for potential outperformance in the market [10].

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) has seen a 13.5% increase in share price over the past four weeks, closing at $39.54, with a potential upside of 29% based on Wall Street analysts' mean price target of $51 [1][12] Price Targets - The average of 10 short-term price targets ranges from a low of $28 to a high of $75, with a standard deviation of $13.58, indicating variability in analysts' estimates [2] - The lowest estimate suggests a decline of 29.2%, while the highest indicates an upside of 89.7% [2] Analyst Sentiment - There is strong agreement among analysts regarding HRMY's ability to report better earnings than previously predicted, which supports the view of potential upside [4][9] - The Zacks Consensus Estimate for the current year has increased by 6.8% over the past month, with no negative revisions [10] Zacks Rank - HRMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of HRMY's potential gains, it does provide a directional guide for price movement [12]

Core Insights - Harmony Biosciences Holdings, Inc. (HRMY) is currently viewed as a better value opportunity compared to Repligen (RGEN) for investors interested in Medical - Biomedical and Genetics stocks [1] Valuation Metrics - HRMY has a forward P/E ratio of 12.06, significantly lower than RGEN's forward P/E of 99.13 [5] - HRMY's PEG ratio stands at 0.51, indicating a favorable valuation relative to its expected earnings growth, while RGEN's PEG ratio is much higher at 4.76 [5] - HRMY's P/B ratio is 3.71, compared to RGEN's P/B of 4.70, suggesting HRMY is more attractively priced relative to its book value [6] Zacks Rank and Style Scores - HRMY holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook, while RGEN has a Zacks Rank of 3 (Hold) [3] - Based on the Style Scores system, HRMY has a Value grade of A, whereas RGEN has a Value grade of D, further supporting HRMY as the preferred choice for value investors [6]

Company Overview - Harmony Biosciences Holdings, Inc. is a Pennsylvania-based commercial stage pharmaceutical company known for marketing and selling Wakix (pitolisant) [2] Investment Insights - The company provides catalysts for investors to look out for, along with buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Analysts have been covering biotech, healthcare, and pharma sectors for over 5 years, producing detailed reports on more than 1,000 companies [2] Analyst Position - The analyst has no current stock, option, or similar derivative position in any of the companies mentioned but may initiate a long position in HRMY within the next 72 hours [3]

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum and an improving earnings outlook [1][2]. Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Harmony Biosciences' earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, the earnings estimate is $0.73 per share, reflecting a +62.22% change from the previous year [4]. - The Zacks Consensus Estimate for the current quarter has increased by 5.49% over the last 30 days, with one estimate moving higher and no negative revisions [4]. - For the full year, the earnings estimate stands at $2.43 per share, representing a +14.08% change from the previous year [5]. - The consensus estimate for the current year has increased by 15.8%, with one estimate moving higher and no negative revisions [5]. Zacks Rank - The positive estimate revisions have led Harmony Biosciences to achieve a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance [6]. - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [6]. Stock Performance - Harmony Biosciences shares have increased by 8.3% over the past four weeks, suggesting investor confidence in its earnings growth prospects [7].

Group 1 - Harmony Biosciences Holdings, Inc. (HRMY) shares have increased by 8.3% over the past four weeks, closing at $36.42, with a mean price target of $50.80 indicating a potential upside of 39.5% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $13.43, where the lowest estimate is $28 (23.1% decline) and the highest is $75 (105.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 15.8% over the last 30 days [9][10] Group 2 - HRMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [7] - While price targets may not be reliable indicators of actual price movements, they can provide a directional guide for potential stock performance [12]

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positiv ...

Company Participation in Industry Events - Harmony Biosciences Holdings Inc will participate in the 43rd Annual J P Morgan Healthcare Conference in San Francisco CA on January 15 2025 [1] - Jeffrey M Dayno MD President and Chief Executive Officer is scheduled to present at the conference at 11:15 am PT 2:15 pm ET [1] - A webcast of the fireside chat will be available on the investor page of Harmony's website [1] Company Overview - Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases [2] - The company is driven by novel science visionary thinking and a commitment to addressing unmet medical needs [2] - Established by Paragon Biosciences LLC in 2017 and headquartered in Plymouth Meeting PA [2] - The company aims to create a better future through therapeutic innovations culture and community programs [2] Contact Information - Investor contact Brennan Doyle can be reached at 484-539-9700 or via email [3] - Media contact Cate McCanless can be reached at 202-641-6086 or via email [3]

Core Viewpoint - Harmony Biosciences Holdings, Inc. has announced a public offering of 8,000,000 shares of its common stock at a price of $31.00 per share, with an additional option for underwriters to purchase 1,200,000 shares [1] Group 1: Offering Details - The offering is being conducted by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC, with J.P. Morgan acting as the sole book-running manager [1] - The company will not receive any proceeds from the sale of shares, as the offering is solely from selling shareholders [1] - The offering is expected to close on November 1, 2024, subject to customary closing conditions [1] Group 2: Regulatory Information - The shares are being offered under an effective shelf registration statement filed with the SEC, and the offering is made only by means of a prospectus supplement and accompanying base prospectus [2] - Preliminary and final prospectus supplements can be obtained free of charge on the SEC's website [2] Group 3: Company Overview - Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases with unmet medical needs [4] - Established in 2017 and headquartered in Plymouth Meeting, PA, the company emphasizes innovation and empathy in its therapeutic advancements [4]